Radiopharm TheranosticsRADX
13F holders, Q3 2025 (September 30)4holders −1
0new positions
1sold out
$5.52avg. 13F price*
At the end of Q3 2025, 4 institutions reported holding Radiopharm Theranostics Ltd. (RADX) in their 13F filings, down 1 from Q2 2025. 0 opened new positions and 1 sold out. The largest holders were Silverarc Capital Management, LLC ($1.0M), Regal Partners Ltd ($502K) and UBS Group AG ($100K).
- Company
- Radiopharm Theranostics Ltd.
- CUSIP
- 75041J101
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $166K |
All 13F filers, Q2 2025 → Q3 2025: 8,451 shares bought and 35,635 shares sold, net −27,184 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Silverarc Capital Management, LLC | 0.15% | No change | 187,406 | $1.0M |
| Regal Partners Ltd | 0.04% | No change | 90,909 | $502K |
| UBS Group AG | 0.00% | Add +2.5% | 18,191 | $100K |
| PNC Financial Services Group, Inc. | 0.00% | Add +100.0% | 16,000 | $88K |
"% of holder's portfolio" is RADX's weight in each manager's 13F, not the share of Radiopharm Theranostics Ltd. the manager owns.